Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665708 | 1.00 | GAA (0.48) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL665796 | 1.00 | GAA (0.48) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL27655693 | 0.81 | MEN1 (0.41) | GAAKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL13181514 | 0.80 | GAA (0.52) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL11131278 | 0.80 | KDM4E (0.58) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL24672244 | 0.78 | GAA (0.50) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL6422868 | 0.78 | GAA (0.50) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL13751420 | 0.78 | GAA (0.50) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL456164 | 0.78 | GAA (0.50) | GAAKDM4EGLAKMT2AMEN1 | |
| SCHEMBL28324473 | 0.78 | GAA (0.41) | GAAKDM4EGLAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375900-B1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA INC (US) | 2016-03-02 | — | — | EP | disclosed |
| CN-102421778-B | Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2013-10-16 | — | — | CN | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| CN-1863794-B | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2012-04-25 | — | — | CN | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20110268699-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | BIOVISTA, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| WO-2011033094-A1 | SCHEDULE OF ADMINISTRATION OF BENZAZOLE DERIVATIVES IN THE TREATMENT OF LEUKEMIAS | 4SC AG (DE) | 2011-03-24 | — | — | WO | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| CN-1030607-C | Tetracyclic compounds having anti-allergic and anti-asthmatic activities, their prepn. and use | SANKYO CO (JP) | 1996-01-03 | — | — | CN | disclosed |
| US-5476848-A | Antihistamines | SANKYO COMPANY, LIMITED (JP) | 1995-12-19 | — | — | US | disclosed |
| US-5461051-A | Tetracyclic compounds having anti-allergic and anti-asthmatic activities and their use | SANKYO COMPANY, LIMITED (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| US-5362725-A | Antiallergens, antiasthmatic | SANKYO COMPANY, LIMITED (JP) | 1994-11-08 | — | — | US | disclosed |
| EP-0505014-A2 | Novel tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use | Sankyo Company Limited (JP) | 1992-09-23 | — | — | EP | disclosed |
| CN-1051360-A | Have agaist allergic symptoms and the active new tetracyclic compound of anti-asthma, its preparation and application | SANKYO CO (JP) | 1991-05-15 | — | — | CN | disclosed |
| EP-0421823-A2 | Novel tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use | Sankyo Company Limited (JP) | 1991-04-10 | — | — | EP | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | GAA 2479/4885KDM4E 2055/4885GLA 2087/4885 |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | GAA 4522/4885KDM4E 3150/4885GLA 4145/4885 |
| US-20110268699-A1 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES | PMP22, AQP4, PLP2 | GAA 2009/4885KDM4E 2788/4885GLA 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.